真实世界实践中影响中轴型脊柱关节炎患者司库奇尤单抗保留的因素:FORSYA回顾性研究结果
FORSYA是一项法国多中心回顾性研究,纳入906例接受司库奇尤单抗治疗的成人中轴型脊柱关节炎患者,1年Kaplan-Meier保留率为59%(95%CI 55%-62%)。多因素分析显示,既往未暴露于TNF抑制剂、无客观炎症征象及合并炎症性肠病与更好的1年保留相关。
要点
- 906例中轴型脊柱关节炎患者1年司库奇尤单抗保留率为59%(95%CI 55%-62%)。
- 有客观炎症征象者1年保留率58%(95%CI 54%-62%),无客观炎症征象者为63%(95%CI 53%-73%)。
- 既往暴露于TNF抑制剂、存在客观炎症征象及合并炎症性肠病是司库奇尤单抗停药的危险因素。
核心结论
- 在法国获批后,日常实践中约59%的中轴型脊柱关节炎患者在1年时仍保留司库奇尤单抗治疗。
- 既往暴露于TNF抑制剂、存在客观炎症征象及合并炎症性肠病被确定为司库奇尤单抗停药的危险因素。
研究设计与样本
- FORSYA是一项法国多中心、非干预性、回顾性研究,纳入2016年8月11日至2018年8月31日期间接受司库奇尤单抗治疗的成人中轴型脊柱关节炎患者。
- 共纳入来自48个中心的906例患者,其中42.2%为男性,平均年龄46.2±11.7岁,平均病程9.3±9.1年。
- 采用Kaplan-Meier分析评估司库奇尤单抗停药时间与保留率,客观炎症征象预先定义为启动司库奇尤单抗时C反应蛋白≥5 mg/L或红细胞沉降率≥28 mm/小时,或骶髂关节或脊柱水平MRI炎症。
主要发现
- 司库奇尤单抗1年Kaplan-Meier保留率为59%(95%CI 55%-62%)。
- 有客观炎症征象患者1年保留率为58%(95%CI 54%-62%),无客观炎症征象患者为63%(95%CI 53%-73%)。
- 多因素分析中,既往未暴露于TNF抑制剂、无客观炎症征象及合并炎症性肠病与1年时更好的司库奇尤单抗保留相关。
关键数值与推荐
- 客观炎症征象预先定义为至少符合以下一项:启动司库奇尤单抗时C反应蛋白≥5 mg/L、红细胞沉降率≥28 mm/小时,或骶髂关节或脊柱水平MRI炎症。
- 1年保留率:总体59%(95%CI 55%-62%);有客观炎症征象者58%(95%CI 54%-62%);无客观炎症征象者63%(95%CI 53%-73%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate. The key objective was to determine whether objective signs of inflammation (OSI) were predictive of secukinumab retention at 1 year. METHODS: FORSYA is a French, multicentric, non-interventional, retrospective study in adult axSpA patients who received secukinumab treatment between its launch (11 August 2016) and 31 August 2018. The time to secukinumab discontinuation and retention were analysed using a Kaplan-Meier (KM) analysis. OSI was predefined by at least one of the criteria: C reactive protein ≥5 mg/L or erythrocyte sedimentation rate ≥28 mm/hour at secukinumab initiation or MRI inflammation at the sacroiliac or spine level. RESULTS: In total, 906 patients from 48 centres were included in the analysis, 42.2% of whom were men, with a mean age of 46.2±11.7 years and a mean disease duration of 9.3±9.1 years. The 1-year KM retention rate (95% CI) for secukinumab was 59% (55%-62%), whereas for patients with and without OSI, it was 58% (54%-62%) and 63% (53%-73%), respectively. In multivariate analysis, lack of prior exposure to tumour necrosis factor inhibitor (TNFi), absence of OSI and inflammatory bowel disease (IBD) were associated with a better retention of secukinumab at 1 year. CONCLUSION: Following its approval in France, ~59% of axSpA patients retained secukinumab in daily practice, at 1 year. Prior exposure to TNFi, OSI and IBD were identified as risk factors for secukinumab discontinuation.
引用
- Dougados M, Lucas J, Desfleurs E, et al. Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD Open. 2023. PMID: 36921980. doi:10.1136/rmdopen-2022-002802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。